NewAmsterdam Pharma
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, NewAmsterdam Pharma sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
NewAmsterdam Pharma: 15 sponsored US clinical trials, 4 recruiting.
NewAmsterdam Pharma sponsors 15 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 9 completed. 6 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lipidemia, with 2 trials.
Top-decile sponsor footprint
NewAmsterdam Pharma ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
15 total, page 1 of 1
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NCT07219602
Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers
NCT06982508
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
NCT06496243
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
NCT06305559
Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
NCT05972278
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
NCT05202509
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
NCT06005597
Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib
NCT06250205
Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe
NCT06050291
PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function
NCT06048302
Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
NCT05425745
Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy
NCT05266586
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
NCT05142722
Randomized Study of Obicetrapib in Combination With Ezetimibe
NCT04770389
Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
NCT04753606
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 5 |
| Phase 3 | 6 |
What is open in the NewAmsterdam Pharma pipeline
4 recruiting of 15 indexed (27% open); 9 completed (60%).
Phase mix: 6 late (III/IV) vs 9 early (I/II) (balanced across stages).
Top condition: Lipidemia (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NewAmsterdam Pharma: open-pipeline peers nationwide
Peers matched on 15 registered trials and 27% open enrollment, not the therapeutic-area sidebar.
NewAmsterdam Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 trials (± recruiting share)
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors near 27% open enrollment (± trial volume)
- Coherus Oncology · 27% recruiting · 15 trials
- Portland VA Medical Center · 27% recruiting · 15 trials
- White River Junction Veterans Affairs Medical Center · 27% recruiting · 15 trials
- University of Illinois at Chicago · 27% recruiting · 430 trials
Related
What to do with this NewAmsterdam Pharma page
15 registered trials is a research-attention snapshot, not an endorsement of NewAmsterdam Pharma or any single study.
- 4 of NewAmsterdam Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lipidemia is the condition NewAmsterdam Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lipidemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NewAmsterdam Pharma pipeline card: 15 registered trials from official public datasets.Report a data error.